HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of Smad7 overexpression on peritoneal inflammation in a rat peritoneal dialysis model.

AbstractOBJECTIVE:
Transforming growth factor-beta (TGF-beta) has been shown to play a role in peritoneal complications due to long-term peritoneal dialysis (PD). In this study, we examined the effects of the TGF-beta signaling pathway on peritoneal inflammation associated with PD in rats by over-expressing Smad7, an inhibitor of TGF-beta/Smad signaling.
METHODS:
Peritoneal inflammation was induced in male Sprague-Dawley rats by intraperitoneal injections of 4.25% glucose dialysate (100 mg/kg body weight) daily for 4 weeks, with the addition of lipopolysaccharides (0.6 mg/kg body weight) on days 8, 10, 12, 22, 24, and 26. Peritoneal Smad7 gene transfer was achieved using an ultrasound microbubble mediated, doxycycline regulated, Smad7-expressing plasmid on day 0 and day 14 after initiation of PD. An empty vector was used as control. All rats were sacrificed after 4 weeks of PD. Peritoneal inflammatory response, including infiltration of total leukocytes (OX-1 positive) and macrophages (ED-1 positive) and expression of interleukin (IL)-1beta and tumor necrosis factor-alpha (TNF-alpha), was examined by immunofluorescence and RT-PCR.
RESULTS:
After PD, peritoneal inflammation developed in control animals, as demonstrated by an increase in the number of OX-1-positive and ED-1-positive cells and upregulation of IL-1beta and TNF-alpha mRNA and protein expression. In contrast, in animals treated with Smad7 gene transfer, IL-1beta and TNF-alpha expression and OX-1-positive and ED-1-positive cell infiltration were significantly inhibited. Furthermore, prevention of peritoneal inflammation by overexpression of Smad7 was associated with inhibition of phosphorylation of Smad2/3, a downstream of the TGF-beta signaling pathway, as well as TGF-beta1 expression.
CONCLUSION:
Overexpression of Smad7 suppresses peritoneal inflammation induced by high glucose and lipopolysaccharides. The ability of Smad7 gene transfer to inhibit peritoneal inflammation indicates that targeting TGF-beta/Smad signaling may represent a new therapeutic strategy for the treatment of peritoneal complications associated with PD.
AuthorsJing Nie, Wenke Hao, Xianrui Dou, Xin Wang, Ning Luo, Hui Y Lan, Xueqing Yu
JournalPeritoneal dialysis international : journal of the International Society for Peritoneal Dialysis (Perit Dial Int) 2007 Sep-Oct Vol. 27 Issue 5 Pg. 580-8 ISSN: 0896-8608 [Print] United States
PMID17704451 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Inflammation Mediators
  • Lipopolysaccharides
  • Smad7 Protein
  • Smad7 protein, rat
  • Transforming Growth Factor beta
Topics
  • Animals
  • Disease Models, Animal
  • Gene Transfer Techniques
  • Inflammation Mediators (administration & dosage, metabolism, physiology)
  • Lipopolysaccharides (administration & dosage)
  • Male
  • Peritoneal Dialysis
  • Peritonitis (genetics, metabolism, pathology, prevention & control)
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction (genetics)
  • Smad7 Protein (administration & dosage, biosynthesis, genetics)
  • Transforming Growth Factor beta (antagonists & inhibitors, biosynthesis, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: